You are here

V114

Merck snags priority review for Prevnar 13 rival — just one month after Pfizer sent its follow-on to the FDA

Merck snags priority review for Prevnar 13 rival — just one month after Pfizer sent its follow-on to the FDA

Endpoints

pneumococcal disease

priority review

Flag link:

Merck's rival to Pfizer's Prevnar 13 hits goal in phase 3 again

Merck's rival to Pfizer's Prevnar 13 hits goal in phase 3 again

Fierce Biotech

clinical trials

pneumococcal disease

Flag link:

Merck’s pneumonia vaccine posts two more hits

Merck’s pneumonia vaccine posts two more hits

EP Vantage

Flag link:

Merck’s Experimental Pneumonia Vaccine Hits the Mark in Two Phase III Studies

Merck’s Experimental Pneumonia Vaccine Hits the Mark in Two Phase III Studies

BioSpace

clinical trials

pneumococcal disease

Flag link:

Looking to topple Pfizer's Prevnar 13 dynasty, Merck claims another win for its 'breakthrough' pneumococcal conjugate vaccine

Looking to topple Pfizer's Prevnar 13 dynasty, Merck claims another win for its 'breakthrough' pneumococcal conjugate vaccine

Endpoints

pneumococcal disease

Flag link:

FDA blesses Merck’s PhIII effort to topple a mega-blockbuster — but there’s also a little biotech in this game

FDA blesses Merck’s PhIII effort to topple a mega-blockbuster — but there’s also a little biotech in this game

Endpoints

breakthrough status

Flag link:

Merck pits its pneumococcal shot against Pfizer's mammoth Prevnar in head-to-head ph3

Merck pits its pneumococcal shot against Pfizer's mammoth Prevnar in head-to-head ph3

Fierce Pharma

pneumococcal disease

Flag link:

Merck CEO: Gardasil plus pipeline equals big things ahead for vaccines

Merck CEO: Gardasil plus pipeline equals big things ahead for vaccines

Fierce Pharma

Moderna Therapeutics

Flag link: